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Abstract
ShinyGPA: An Interactive and Dynamic Visualization Toolkit for the
Exploratory Analysis of Genetic Studies
by
Emma Kortemeier
As of this year, genome-wide association studies (GWAS) have identified over 20,000 single nucleotide polymorphisms (SNPs) associated with at least one disease or trait. Such
achievements have provided various clinical and medical benefits with novel biomarkers
and therapeutic targets. Recently, there has been accumulating evidence suggesting that
different complex traits share common risk basis, a phenomenon known as pleiotropy.
For example, 17% of genes reported in the GWAS Catalog are associated with more than
one phenotype. Thus, a better understanding of pleiotropy can potentially be clinically
beneficial as it may facilitate understanding of the common etiology of diseases and
help improve therapies. However, effective interrogation of pleiotropic architecture still
remains challenging, and it often requires employment of complicated statistical models. In order to address these challenges, we are developing ShinyGPA, an interactive
and dynamic visualization toolkit for exploratory analysis of genetic studies. Specifically, ShinyGPA maps phenotypes onto two-dimensional space based on the genetic
relationship among these phenotypes. In addition, ShinyGPA provides remarkable flexibility in modifying visualization to help improve user interpretations. The application
of ShinyGPA to simulated data illustrates that the tuning parameter we have intro-

duced provides a zoom functionality. Additionally, the application of ShinyGPA to
GWAS datasets for 12 unique phenotypes indicates that clinically related phenotypes
form clusters in the phenotype map generated by ShinyGPA. In addition, the visualization produced by ShinyGPA provides interesting hypotheses for relationships among
groups of phenotypes, which require further investigation and in turn can be useful
for the design of future genetic studies. We expect that ShinyGPA will be a powerful
and flexible off-the-shelf tool to elucidate the genetic relationship among phenotypes,
which can contribute to the development and improvement of diagnoses and therapeutics for various diseases. The R implementation of ShinyGPA is currently available at
http://dongjunchung.github.io/GPA/.
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Chapter 1
Introduction and Background

1.1

Genome-wide Association Studies (GWAS)
Genome-wide association studies (GWAS) are a modern approach to scientific

inquiry, with the first GWAS published in 2005-2007 [1, 2, 3]. The aim of GWAS is to
identify variants in the genome (specifically, single nucleotide polymorphisms, or SNPs)
that are associated with human complex traits or diseases on the population level. The
GWAS approach is founded on the theory of population level linkage disequilibrium
(LD). LD is the non-random association of alleles at different loci on the chromosome.
LD occurs when the frequency of the association between alleles is higher than that
which would be expected if the loci were independent and randomly associated, i.e.
that which is expected by chance. Generally speaking, loci that are closer together on
the chromosome exhibit stronger LD compared to loci that are farther apart. Utilizing
an understanding of this relationship, it is possible to capture the common variation in
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non-African populations using around 500,000 SNPs, which represents under 5 percent
of the total number of common SNPs (minor allele frequency, MAF, > 5%) [4]. GWAS
are typically designed as population-based, case-control association studies [5]. That is
to say, the frequency of minor allele SNPs is compared between individuals that have
the trait of interest (cases) and those that do not (controls). GWAS statistical analysis
approaches include SNP-wise chi-square tests of association, likelihood ratio tests, and
in multivariate settings, logistic regression. In all of these cases, it is important to
account for multiple testing.
Before the recognition of the LD structure of genes and the increased accessibility of SNP chips (arrays that capture most of the common variation in the genome),
genetic studies were restricted to candidate gene approaches. In this setting, smaller
sample sizes were used, only a few variants were analyzed, and the results were difficult
to replicate [6, 7]. The only other widely used approach before GWAS was family based
linkage studies, where a host of genomic markers (often hundreds to thousands) are
traced back to inheritance patterns. These types of studies made progress in the area of
single gene, Mendelian disorders [8, 9], but were limited in their applicability to complex
traits or disorders, due to their low power and low variant resolution [10, 11, 12].
The results and knowledge gained from GWAS can improve the likelihood of
success of drug development and clinical trials. Drug mechanisms that have known
genetic associations are more likely to make it through the drug development pipeline
to approval [13, 14, 15, 16].

2

1.2

Polygenicity
One important initial insight gained from GWAS in the last ten years is that

variants, taken individually or combined, have a small effect sizes (odds ratios often
between 1.1-1.5) [17, 18]. In addition, the proportion of phenotypic variation accounted
for by statistically significantly associated SNPs is generally low (approximately 10
percent)[19]. For example, about 180 SNPs have been reported as significantly association with human height [20]; however, together these SNPs only explain between 5
and 10 percent of the variation in height [21, 22, 20]. Thus, given the limited sample
size of GWAS, many individual effects of genetic variants are too small to pass genomewide significance, and remain unidentified, contributing to the yet unexplained genetic
variation [23]. This phenomenon of many genetic variants, each with small or weak
effect sizes which cannot be identified via traditional statistical tests, affecting a single
phenotype is called polygenicity.
Polygenicity of complex traits has been corroborated by more recent GWAS
with larger samples sizes, allowing more associated SNPs with mild effects to be identified [24]. In this case, Morris et al. [24] used polygenic mixed linear modeling on
two GWAS datasets to estimate the contribution to the variance in type 2 diabetes by
common variants across the genome. Based on these analyses, Morris et al concluded
that a substantial proportion of the variation in type 2 diabetes risk is due to common
variants, that individually are not significant in single SNP analyses.

3

1.3

Pleiotropy: Biological Evidence
Another important insight gained from GWAS is the concept of pleiotropy,

or a common genetic basis shared between distinct phenotypes. There is evidence of
associated loci in common among diseases not previously known to share an etiology
[17].
In fact, according to Sivakumaran et al., 16.9 percent of genes and 4.6 percent
of SNPs reported in the GWAS catalog are associated with more than one trait [25]. In
this case, the authors define pleiotropy as “a single gene or variant being associated with
more than one distinct phenotype (disease endpoints or quantitative traits)”. Association is defined as genetic variants reported to be associated with a complex trait at the
genome-wide significance level of p < 5 × 10−8 [26]. Sivakumaran et al. found pleiotropy
between fetal hemoglobin and malaria (p = 0.0009), gallstones and serum campesterol
(p = 0.0008), immunoglobulin A and juvenile idiopathic arthritis (JIA) (p = 0.0008),
and knee osteoarthritis and narcolepsy (p = 0.0009), among others.
More recently, in a paper from 2013 [27], Andreassen et al used a pleiotropic
enrichment method to better detect schizophrenia-associated SNPs. The authors were
able to identify the SNPs with more power by leveraging the pleiotropic relationship
between schizophrenia and cardiovascular disease risk factors, specifically triglycerides
and waist-to-hip ratio.
In a 2014 study by the Cross Disorder Group of the Psychiatric Genomics Consortium (PGC) [28], four loci were found to have significant (p < 5×10−8 ) pleiotropic ef-
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fects between the five psychiatric disorders: autism spectrum disorder, attention deficithyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia.
Further investigation into the genetic relationships among the five previously mentioned
psychiatric disorders yeilds a strong, significant genetic correlation, or coheritability, between schizophrenia and bipolar disorder [29].

1.4

Pleiotropy: Statistical Approaches
To analyze pleiotropy statistically, the Sivakumaran et al. [25] applied an

outlier detection approach previously applied in astronomy [30] and, more recently, in
machine learning [31]. They call this the degree of surprise (DS) approach. In the
context of genetics, this approach determines whether the number of matching genetic
variants shared by two traits is significantly larger than the number of matching variants
expected by chance between any random pair of traits. Specifically, they assume that
mismatching genetic causes between traits is an indicator of dissimilarity. Thus, the
DS approach assigns a status of pleiotropy to pairs of phenotypes with high numbers of
matching variants and low numbers of mismatching variants. This approach is an improvement over previous models, as it does not make the assumption that all phenotypes
are unrelated, nor does it make the assumption that every gene has the same probability of being associated with every phenotype. However, this approach does make the
assumption that genetically related phenotypes are relatively infrequent, which may not
be an appropriate assumption. A DS p-value is obtained by considering the likelihood
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ratio of similarity and dissimilarity models. To avoid over-representing the prevalence
of pleiotropy, Sivakumaran et al. excluded phenotypes that are counterparts, subsets
of each other, calculated based on each other, potential measures of the same genetic
effect, and known causal factors of each other.
Another approach is a pleiotropic enrichment method based on a conditional
false discovery rate (FDR) approach [27]. Andreassen et al. use the FDR to calculate
the true discovery rate (T DR = 1 − F DR). Here FDR is defined as:

F DR (p) =

π0 p
,
F (p)

where π0 is the proportion of null SNPs, p is a predefined p-value cutoff and F (p) is the
is the cdf of all SNPs including null and non-null. A key concept regarding conditional
FDR is stratification, or the evaluation of QQ plots for a phenotype conditional on
another phenotype. Thus, the authors also employ stratified QQ plots to assess degree
of pleiotropy, represented as degree of deflection from the diagonal line. Andreassen et
al. note that a TDR close to one corresponds to a greater degree of deflection from the
diagonal in the QQ plot, and thereby, a greater degree of pleiotropy between the two
phenotypes.
In a Psychiatric Geomics Consortium (PGC) paper [28], the authors used a
risk-score profiling approach, originally described in a paper by Purcell et al. [29].
In the risk-score approach, one first defines fairly liberal (genome-wide significance)
p-value thresholds, for example p < 0.1 or p < 0.5. Then employing the thresholds,
it is possible to define large groups of “score alleles” in a discovery dataset. In this
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case, one creates aggregate risk scores for independent target datasets, and applies a
Cochran-Mantel-Haenszel test to test for significance of pleiotropy.
In the PGC paper [28], the authors analyzed pairs of disorders among the
five psychiatric disorders: autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia. For each pair,
one diagnosis was chosen as the discovery dataset and the other diagnosis taken as
the target dataset. It is then possible to calculate the proportion of variance (via the
Nagelkerkes pseudo R2 ) of the target dataset that is explained by the risk scores of the
discovery dataset. It is possible to examine the proportion of variance at increasingly
liberal p-value cutoffs, to more fully explore the potentially pleiotropic relationships.
In this case the authors used six cutoffs: p < 0.05, p < 10−4 , p < 10−8 , p < 10−12 ,
p < 10−16 , p < 10−50 [24]. In this way, the authors were able to identify four loci that
have pleiotropic effects between the five psychiatric disorders studied.
In a paper that further investigates the five psychiatric diseases [32], correlation
is defined as positive when the cases of one disease, say schizophrenia, exhibit higher
genetic similarity to the cases of another disease, say bipolar disorder, than they do to
their own controls. If the cases are less similar to cases of another disease compared
to their own controls, the correlation is defined as negative. If the cases are equally
similar to the cases of another disease and their own control, the correlation is 0. The
SNP-based coheritability is defined as the covariance between the two diseases on the
liability scale. The liability scale entails applying a linear transformation based on
an estimate of the risk of the disease in the population. The coheritability between
7

schizophrenia and bipolar disorder was strong at 0.68 (s.e.= 0.04), moderate between
schizophrenia and major depressive disorder, bipolar disorder and major depressive
disorder, and between ADHD and major depressive disorder. Thus, there is evidence of
strong pleiotropy between schizophrenia, bipolar disorder, and major depressive disorder
especially, among the 5 psychiatric disorders investigated.

1.5

Genetic Analysis Incorporating Pleiotropy and Annotation (GPA)
Due to the increasing availability of GWAS results, the recent awareness of

polygenicity and pleiotropy, it is desirable to develop a methodology that both increases
the power to detect small effect sizes in a host of variants and leverages the potentially
pleiotropic relationship between phenotypes. To this end, the GPA (Genetic analysis
incorporating Pleiotropy and Annotation) approach has previously been developed [23].
One of the major strengths of the GPA approach is that it requires only the GWAS
summary statistics, which are considerably easier to obtain than the full genotypic data.
Let pmk represents the p-value for the m-th SNP from the k-th GWAS. In
the two phenotype case, let p11 , p21 , . . . , pm1 , . . . , pM 1 be the p-values for M SNPs from
the first GWAS. Similarly, let p12 , p22 , . . . , pm2 , . . . , pM 2 be the p-values from the second
GWAS. Here, p-values can be obtained from a χ2 -test or a logistic regression in the
context of a case-control GWAS.
Next we define a latent variables Zm = {Zm00 , Zm10 , Zm01 , Zm11 } to indicate
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the association between the m-th SNP and the two phenotypes of interest. Zm00 = 1
denotes the case where the m-th SNP is not associated with either of the phenotypes,
Zm10 denotes the case where the m-th SNP is associated with only the first phenotype,
Zm01 denotes the case where the m-th SNP is associated with only the second phenotype, and lastly, Zm11 denotes the case where the m-th SNP is associated with both
phenotypes of interest. Here we assume that a SNP can only be in one of these states.
Given Zm , we assume the following distributions of p-values:

π00 = P r (Zm00 = 1) :
(pm1 |Zm00 = 1) ∼ U [0, 1]
(pm2 |Zm00 = 1) ∼ U [0, 1]
π10 = P r (Zm10 = 1) :
(pm1 |Zm10 = 1) ∼ Beta (α1 , 1)
(pm2 |Zm10 = 1) ∼ U [0, 1]
π01 = P r (Zm01 = 1) :
(pm1 |Zm01 = 1) ∼ U [0, 1]
(pm2 |Zm01 = 1) ∼ Beta (α2 , 1)
π11 = P r (Zm11 = 1) :
(pm1 |Zm11 = 1) ∼ Beta (α1 , 1)
(pm2 |Zm11 = 1) ∼ Beta (α2 , 1)

9

Note that 0 < α1 , α2 < 1 ensures that a smaller p-value is more likely than a larger
p-value when it is from an associated group. Figure 1.1 illustrates how different values
of α in the Beta distribution model associated p-values. In the case where α = 1 it is a
Uniform distribution.
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Figure 1.1: Histograms of Beta(α, 1) for different values of α

In order to test for pleiotropy using GPA, hypothesis testing is employed. Table
1.1 provides a visualization for how the null hypothesis is obtained. The null hypothesis
is:
H0 : π11 = (π10 + π11 )(π01 + π11 )
where
π11 : proportion of SNPs associated with both phenotypes
π10 : proportion of SNPs associated with only the first phenotype
π01 : proportion of SNPs associated with only the second phenotype
10

π00 : proportion of SNPs associated with neither phenotype
P1 background

P1 associated

P2 background

π00

π10

P2 associated

π01

π11

π01 + π11

π10 + π11

1

marginal

marginal

Table 1.1: Cross tabulation illustrating how the null hypothesis is obtained. P1 is the
phenotype for the first GWAS and P2 is the phenotype for the second GWAS.

It is then possible to construct the likelihood ratio test statistic

λ(P )
(P )

where Θ̂0



(P )
Pr P; Θ̂0

 ,
=
Pr P; Θ̂

(1.1)

is the parameter estimates under the null hypothesis and P indicates the

test for pleiotropy (as opposed to the test for annotation enrichment, not covered here).
The −2 log λ(P ) asymptotically follows a χ2 distribution with 1 degree of freedom; thus,
it is possible to obtain a pleiotropy p-value for the pair of phenotypes (yij ).

1.6

Aim
The aim of this thesis is to develop an effective visualization approach to in-

vestigate pleiotropy. This includes creating an interactive and dynamic visualization,
introducing a flexible distance transformation, and investigating clustering between phenotypes.

11

Chapter 2
Methods

In order to effectively utilize pleiotropy, while leveraging data from multiple
GWAS, Chung et al. have previously developed a unified statistical framework called
GPA (Genetic analysis incorporating Pleiotropy and Annotation)[23]. The GPA approach supplies statistically rigorous and biologically interpretable inference tools for
genetic studies. Unfortunately, GPA is limited to only a few phenotypes, usually considering a joint analysis of only two at a time, due to the computational intensity,
estimation stability, and robustness. To this end, a visualization approach has been
developed, namely GPA-MDS, which investigates genetic architecture through a joint
analysis of GWAS data, using the GPA algorithm followed by a multi-dimensional scaling approach [33]. After analyzing the GWAS datasets of interest two-at-a-time, the
multidimensional scaling (MDS) approach integrates the results and produces a twodimensional visualization representing the genetic architecture between many phenotypes.

12

The GPA-MDS approach has some weakness, specifically, the visualization is
static and somewhat rigid, there is little guidance for interpretation, and the there is
no explanation for which SNPs are driving the relationships. In order to address these
issues, I present ShinyGPA.

2.1

Pleiotropy Visualization Using GPA-MDS
To begin, we will review the GPA-MDS approach to visualization. The GPA-

MDS approach to visualization begins by analyzing all pairs of phenotypes of interest
using the GPA algorithm. Wei et al. then apply a log10 transformation to the pleitropy
test p-value matrix (yij ), which is popular in the literature [34, 35], and defines the
distance between the i-th and j-th phenotypes as dij = sij − 2mink<1 {skl }, where sij is
the log10(yij ). This is to make sure that all of dij values are sufficiently far from zero.
Next, the distance matrix acts as input to the MDS algorithm, which then
projects the phenotypes onto a two dimensional space. In this way, phenotypes sharing
a smaller number of SNPs are further apart in the two dimensional space compared to
phenotypes sharing a larger number of SNPs [33].
The MDS algorithm performs dimension reduction in such a way that the goal
is to place the objects (here phenotypes) in P-dimensional space (here 2 dimensions) so
that the distances among objects are preserved as well as possible. Specifically, given a
distance matrix D = (dij ), MDS seeks to find the representation x1 , . . . , xn ∈ Rp such
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that
dˆij = kxi − xj k2
by minimizing the following objective function:
P



dij − dˆij

P

d2ij

i<j

i<j

2
.

In this case, p = 2 to create a two dimensional plot.
The MDS algorithm can be described in three steps [36]. First, measures of
similarity are obtained for each distinct pair of objects, and the similarities are ordered
from largest to smallest. Next, using a trial configuration, the inter-item distances are
determined which minimize the objective function shown above. Lastly, the points are
moved around to obtain an improved configuration. This process is repeated until the
best (minimum objective function) representation is obtained. The function cmdscale()
in R with default settings is used to implement MDS in the GPA-MDS approach.
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2.2

Pleiotropy Visualization Using ShinyGPA

GWAS summary
p-values
(𝑝𝑝𝑚𝑚𝑚𝑚 , 𝑝𝑝𝑚𝑚𝑚𝑚 )

Pleiotropy distance
matrix of p-values
(𝑦𝑦𝑖𝑖𝑖𝑖 )
ShinyGPA:
Box-Cox, MDS,
Shiny app
(𝑠𝑠𝑖𝑖𝑖𝑖 (𝜆𝜆) , 𝑥𝑥𝑙𝑙 )

GPA (test for
pleiotropy)

Pleiotropy
distance matrix of
p-values (𝑦𝑦𝑖𝑖𝑖𝑖 )

Pleiotropy
Visualization (𝑥𝑥𝑙𝑙 )

Figure 2.1: Summary of work flow for the ShinyGPA visualization approach.

Figure 2.1 shows the workflow of the ShinyGPA framework. Specifically, starting from the summary statistics of multiple GWAS (pmi , pmj ), the GPA algorithm is
applied to each pair and obtain a pleiotropy distance matrix of p-values (yij ). Then,
using this as input for the Shiny app, which includes a Box-Cox distance transformation
(λ)

(sij ) and MDS (xl ), we are able to create a dynamic, flexible pleiotropy visualization.
Here we will explore the improvements over GPA-MDS that make up ShinyGPA. The
first improvement concerns the lack of flexibility in the GPA-MDS visualization.
As mentioned previously, the output from the pleiotropy testing is a type of
distance matrix representing the pleiotropic distance between each pair of phenotypes.
It is important to note that while p-values can range from 0 to 1, the information is
not equally distributed over this range. In fact, in terms of p-values in general, the
important information is concentrated around 0, and thus we are more interested in the
15

values close to 0 compared to those farther away. Since the visualization and clustering
techniques we use do not take into account this skewed distance structure, it is necessary
to modify the distance measure so that it is more meaningful for the methods.
The log10 transformation approach to expanding the information around 0
used in GPA-MDS is too rigid for what we are trying to accomplish. So, in order
to create a more flexible distance measure, we decided on a Box-Cox transformation
(equation 2.1), which allows for a dynamic, zoom-in/zoom-out functionality, i.e.,

(λ)

sij =




 yijλ −1

 λ

if λ 6= 0,





ln (yij )

if λ = 0

(2.1)

where yij is the pleiotropy test p-value matrix and λ is a tuning parameter.
We have left the choice of λ up to the user, which is where the flexibility
comes in. Negative values farther from 0 will create a zoomed out, bird’s eye view
visualization while values above 0 create a zoomed in, detailed look at the pleiotropic
structures. λ = 0 is equivalent to a log10 distance transformation, which was used in
the GPA-MDS approach. In this sense, GPA-MDS can be considered as a special case
of ShinyGPA framework. Figure 2.2 illustrates the consequence of different λ choice for
the Box-Cox transformation. The plots have the original p-values (yij ) on the x-axis and
(λ)

the transformed p-values (sij ) on the y-axis. Thus, the diagonal line produced with
λ = 1 represents no transformation. A curve above the diagonal represents expanding
the information around 0. The higher the point of inflection of the curve is, the more
the small p-values are being expanded and the more zoomed out the plot will be.
16

(λ)

Figure 2.2: Raw p-values (yij ) and transformed p-values (sij ) in the Box-Cox transformation for different λ values.

After applying a Box-Cox transformation to the pleiotropy distance matrix
(yij ), we apply isometric feature mapping (isomap) to reduce the dimensionality of
the phenotypic relationships onto a two dimensional plot [37]. We chose isomap over
more classic cmdscale to avoid the coordinates flipping on successive iterations of the
algorithm. The isomap algorithm works in three steps [37]. First, a neighborhood graph
G is constructed over all the data points by connecting points i and j if either they are
closer than some defined , or if i is one of the k (pre-defined) nearest neighbors of j.
Then, it sets edge lengths to dx (i, j). The next step is to compute the shortest paths.
This is done by initializing dG (i, j) = dx (i, j) if i and j are linked by an edge, and set
dG (i, j) = ∞ otherwise. Then for each value of k, replace all entries of dG (i, j) with
min{dG (i, j) , dG (i, k)+dG (k, j)}. The resulting matrix of final values DG = {dG (i, j)}
17

will contain the shortest path distances between all pairs of points in G. The third step
is to apply classical multidimensional scaling to DG . This constructs an embedding of
the data in a P-dimensional space that best preserves the geometry. The coordinate
vectors xi for points in X are chosen to minimize the objective function:

E = kτ (DG ) − τ (DX ) kL2 ,
where DX indicates matrix of Euclidean distances {dX (i, j) = kxi − xj k} and kAkL2
qP
2
is the L2 matrix norm
i,j Ai,j . The τ operator converts distance to inner products.
The global minimum of the objective function is achieved by setting the coordinates
xi to the top d eigenvectors of the matrix τ (DG ). In this way, we are able to graph
the phenotypic relationships in a two dimensional plot. We used the isomap() function
in R with epsilon=0.15 and ndim=2 to implement the isomap algorithm. We chose
epsilon=0.15 because this is the smallest value that does not introduce the error of
fragmented data.
The next improvement concerns the issue that GPA-MDS provides little guidance for interpretation of the phenotypic relationships shown. To address this, we applied a clustering function to a phenotype plot. This guides interpretation by producing
different colored and shaped clusters to show which phenotypes are genetically closer together. The user is able to determine the number of clusters shown which adds another
element of flexibility to this approach. In addition the user is able to choose between kmeans or hierarchical clustering approaches, applied to the coordinates generated from
isomap that are already Box-Cox transformed.
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K-means clustering is a clustering approach that partitions n observations into
k clusters in such a way as to minimize the within-cluster sum of squares, which is a
sum of the distance functions of each point in the cluster to the center. The k-means
algorithm aims to minimize the objective function

J=

K
X
X

kxl − x̄k k2 ,

k=1 C(l)=k

k is the predefined number of clusters, C(l) = k indicates that l-th point belongs to the
k-th cluster, xl is a point, x̄k is the cluster center (centroid) for the k-th cluster, and
kxl − x̄k k2 is a chosen distance measure between the point and the center. Here, we
allow users to choose k to provide additional flexibility [38].
The k-means process is optimized by first placing k points in the space. These
represent the initial centroids of the k clusters. Next, each data point is assigned to
the cluster with the nearest centroid. After each point has been thus assigned, the
centroids are recalculated. The steps of data point assignment and centroid calculation
are repeated until the position of the centroids no longer moves. We used the kmeans()
function in R with default settings to implement the k-means clustering.
Hierarchical clustering begins by defining each data point as its own cluster.
Next, the distances between each pair of clusters is compared and the two closest clusters
are combined. Now, the distances are remeasured between each pair of clusters and the
next closest pair are combined. This process continues until all the data points are
combined into one cluster. There are multiple approaches to computing the distances
between clusters, which are provided as options in ShinyGPA. We used the hclust()
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function in R to implement the heirarchical clustering.

2.3

Shiny App
The shiny app is currently designed so that the interactive input options are

listed on the left and the dynamic plot output is located on the main, center part of the
screen.
The Shiny app technology is notable for its ability to create dynamic data
visualizations. In my app specifically, the user is able to choose visualization characteristics like which phenotypes are plotted, the number of clusters the phenotypes are
partitioned into, and how far zoomed in or zoomed out they want to view the data.
After the user specifies a setting, the plot automatically updates, making this tool ideal
for exploring pleiotropic relationships within the data. The interactive nature of the app
allows the user to play with the data and see how different choices (clustering methods
or λ value for example) affect the interpretation of the degree of pleiotropy present.
Figure 2.3 shows the layout of ShinyGPA. Of particular note is the upload field,
which allows the user to upload the input matrix. Below the file input field is the plot
title input field. Next, there is a group of phenotype check boxes. By unchecking the
boxes, the user is able to customize the pleitropy visualization to the specific phenotypes
of interest. This feature is helpful for exploring pleiotropic relationships as phenotypes
can easily be removed and added back in with a simple click. Another important input
feature is the group of clustering controls. The user is able to choose the number of
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clusters as well as the clustering approach. After deciding between the k-means and
hierarchical approaches, the user can specify options for them. The phenotypes are
clustered by shape as well as by color, so that the results are clear even if the plot is
eventually printed in gray scale. Below the clustering options, there are the distance
transformation controls. This includes the λ slider bar which provides zoom-in / zoomout functionality as well as a small plot to show how the lambda choice is transforming
the p-values. There are are fields to customize the λ slider bar itself, if the user so
desires.
Near the bottom of the control panel are fields that adjust the font size of
both the phenotype labels on the graph and the coordinate labels; this allows the user
to optimize the visualization for downloading purposes. Lastly, at the bottom of the
input options, there is a download button which allows the user to download a Portable
Document Format (PDF) file of the plot, including the title. The file is automatically
named YourPlotTitle-Shinyplot.pdf.
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Figure 2.3: ShinyGPA screenshot.
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Chapter 3
Results

3.1

Simulation Studies
We simulated 5 phenotypes such that each phenotype has 20% associated SNPs

and 80% background SNPs. We set the associated SNPs of all five phenotypes to have
a 4% overlap, which is what is expected by chance; since, assuming no pleiotropy, the
overlap expected by chance is 0.2 ∗ 0.2 = 0.04. In addition, we set phenotype 1 (P1) and
phenotype 2 (P2) and phenotype 3 (P3) and phenotype 4 (P4) to have varying degress
of extra overlap (Figure 3.1). In all scenarios, phenotype 5 (P5) is set to be independent
and not have extra overlap with any other phenotype. Using the GPA generative model,
the p-values of the associated SNPs (risk SNPs) are defined to have a Beta distribution
with the α parameter representing strength of association and β = 1. We considered
a strong genetic signal, which corresponds to α = 0.4. The p-values of the background
SNPs (non-risk SNPs) were simulated from a uniform distribution.
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Figure 3.1: Four different simulation settings with varying extra overlap
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Figure 3.2: shinyGPA plots for four different simulation settings with varying extra
overlap

Figure 3.1 provides a visual for the simulation settings, specifically how we
designed the 5 phenotypes to overlap. Figure 3.2 provides the corresponding ShinyGPA
plots. From these figures, we see that as the extra overlap between phenotypes increases,
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the distance between the points on the plot decreases. In addition, in the case of the
mixed overlap (Figure 3.1d), ShinyGPA correctly plots P3 and P4 nearer to each other
than P1 and P2, with P5 being furthest away of all (3.2d).
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Figure 3.3: ShinyGPA plots with the same 25% extra overlap, but with varying λ values
to illustrate flexibility of the distance transformation
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Figure 3.3 shows the visualization flexibility provided by the λ parameter. The
same simulation data was used for all three plots (extra 25% overlap; Figure 3.1a). Here
different λ values were chosen in order to illustrate the distance flexibility. When λ = 0,
we have a classic log10 transformation. When λ is negative, it acts as a ”zoom-out”
transformation, allowing the overall relationships among the phenotypes to be visualized. On the the other hand, when λ is positive, it acts as a ”zoom-in” transformation,
allowing a more detailed look into the pleiotropic relationships.
In summary, this simulation study showed that ShinyGPA can recover true
genetic relationships among phenotypes and provide desirable flexibility using the λ
parameter.

3.2

Real Data Analysis
We used the summary statistics from 12 GWAS datasets as input for ShinyGPA.

We were interested in the relationships among these 12 phenotypes, including the pysciatric disorders: attention deficit-hyperactivity disorder (ADHD), autism spectrum disorder (ASD), bipolar disorder (BPD), major depressive disorder (MDD) and schizophrenia
(SCZ) from the Psychiatric Genomics Consortium (PGC) (http://www.med.unc.edu/
pgc)[32, 39]; the autoimmune disorders: Crohn’s disease (CD) and ulcerative colitis
(UC) from the International Inflammatory Bowel Disease Genetics Consortium (IIBDGC) (http://ibdgenetics.org), and rheumatiod arthritis (RA) from the Broad Institute
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(http://www.broadinstitute.org/ftp/pub/rheumatoid_arthritis/Stahl_etal_2010NG/)
[40, 41, 42] ; the lipid related phenotypes: high-density lipoprotein (HDL) from the
Global Lipids Consortium (GLC) (http://csg.sph.umich.edu//abecasis/public/
lipids2010/), and type 2 diabetes (TD2) from the DIAbetesGenetics Replication and
Meta-analysis Consortium (DIAGRAM) (http://diagram-consortium.org) [43, 24];
and the cardiovascular phenotypes: coronary artery disease (CAD) from the CARDIoGRAM Consortium
(http://www.cardiogramplusc4d.org/downloads/), and systolic blood pressure (SBP)
from the International Consortium for Blood Pressure (ICBP)
(http://georgehretlab.org/icbp_088023401234-9812599.html) [44, 45]. Table 3.1
provides detailed information regarding the real data.
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Coronary Artery Disease
Systolic Blood Pressure

SBP

ICBP

CARDIoGRAM

DIAGRAM

GLC

IIBDGC

IIBDGC

Broad Institute

PGC

PGC

PGC

PGC

PGC

Source

**

60,801

12,171

*

6,687

3,230

5,539

9,379

9,227

6,990

4,788 trio; 161

1,947 trio; 840

Num. of Cases

Table 3.1: Details of Real Data.

** 200,000 total cases and controls

* 196,476 total cases and controls

Crohn’s Disease

CD

CAD

Rheumatoid Arthritis

RA

Type 2 Diabetes

Schizophrenia

SCZ

T2D

Major Depressive Disorder

MDD

High-Density Lipoprotein

Bipolar Disorder

BPD

HDL

Autism Spectrum Disorder

ASD

Ulcerative Colitis

Attention Deficit/ Hyperactivity Disorder

ADHD

UC

Phenotype

Abbrev.

**

123,504

56,862

*

19,718

4,829

20,169

7,736

7,383

4,820

4,788 trio; 526

1,947 trio; 688

Num. of Controls

2,500,000

5,900,000

2,500,000

187,576

1,100,000

635,547

2,560,000

1,237,959

1,232,794

1,233,533

1,245,864

1,230,535

Num. of SNPs

European

European

European

Majority European

European

European

European

European

European

European

European

European

Ancestry

Figure 3.4 shows the ShinyGPA visualization of the 12 enumerated phenotypes.
With 3 clusters and λ = 0 defined, we see that the psychiatric phenotypes make a cluster,
the autoimmune diseases make a cluster, and the lipids and cardiovascular phenotypes
make a third cluster.
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Figure 3.4: ShinyGPA output for the real data with 3 clusters chosen with λ = 0.

In the k = 3 and λ = 0 case, the cluster made of up RA, UC, and CD is
supported in the literature as they are all three autoimmune diseases [46]. There is also
evidence of pleiotropy among the five pysciatric disorders, which supports the cluster
made up of ASD, MDD, ADHD, SCZ, and BPD. [28, 29, 32, 27].
When we increase the number of clusters to 5 and keep λ = 0, as in figure
3.5, we see that UC and CD make a cluster, RA is its own cluster, the five psychiatric
phenotypes make the third cluster, SBP is its own cluster, and the rest of the lipid and
cardiovascular phenotypes make the fifth cluster.
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Figure 3.5: ShinyGPA output for the real data with 5 clusters chosen and λ = 0.

In figure 3.6, we investigate the relationship among the autoimmune and lipid
phenotypes, leaving out the psychiatric phenotypes for now. Again, we see SBP making
its own cluster, the autoimmune phenotypes making a cluster, and CAD, T2D, and
HDL forming a third cluster.
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Figure 3.6: ShinyGPA output for the autoimmune and lipid related phenotypes λ = 0.

In figure 3.7 we looked at the relationships among the psychiatric and lipid
related phenotypes only. Here, it is interesting to note that bipolar disorder (BPD) and
schizophrenia (SCZ) are quite distant from the other three psychiatric disorders. In
fact, when we set the number of clusters to 3, we see that BPD and SCZ make their
own cluster. This is supported in the literature, as mentioned in the Introduction and
Background section of this paper [29].
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Figure 3.7: ShinyGPA output for the psychiatric and lipid related phenotypes λ = 0.

Next in figure 3.8 we looked at the pleiotropy among the psychiatric and autoimmune related phenotypes. Again, we see that BPD and SCZ make their own cluster,
separate from the other three psychiatric phenotypes.
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Figure 3.8: ShinyGPA output for the psychiatric and autoimmune related phenotypes
λ = 0.

Lastly, we looked at each of the three main clusters seperatly, excluding the
autoimmune, three points was too sparse of data. In figure 3.9 we see that BPD and SCZ
make one cluster, ADHD and autism spectrum disorder (ASD) make another cluster,
and major depressive disorder (MDD) is off by itself. In figure 3.10 we see that systolic
blood pressure (SBP) is further from the other phenotypes; however, in this case, they
are plotted fairly uniformly across the space.
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Figure 3.9: ShinyGPA output for the psychiatric related phenotypes λ = 0.
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Figure 3.10: ShinyGPA output for the lipid related phenotypes λ = 0.

So, in addition to supplying visualization of known relationships among pheno-
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types, ShinyGPA also can introduce novel relationships that can generate new hypothesis for future research e.g., cardiovascular and lipid-related phenotypes (CAD, HDL,
SBP, and T2D). Thus, ShinyGPA is a useful tool for exploring pleiotropy among many
phenotypes, which in turn leads to a more complete understanding of the etiology of
diseases, disorders, and phenotypes.
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Chapter 4
Discussion

Here I have presented a novel approach to visualizing pleiotropy, namely ShinyGPA,
by extending the GPA-MDS visualization approach. The GPA framework is a rigorous assessment of pleiotropy, and GPA-MDS extends this analysis to many phenotypes in an efficient manner [23, 33]. ShinyGPA builds on this strong foundation by
providing a flexible and interactively dynamic visualization that has guidance for interpretation. Key features include a Box-Cox based distance transformation, an interactive experience, and clustering to guide interpretation. In addition, ShinyGPA
offers an uploading function for the input data and a downloading function to save a
PDF file of the plot. ShinyGPA is available within the GPA R package (available at
http://dongjunchung.github.io/GPA/) providing a seamless integration. This allows
the user to pinpoint specifically which SNPs are driving the visualization.
ShinyGPA can be improved further as follows: (1) Generally, there may be
better ways to compare visualizations. This could include incorporating a data driven
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determination of the number of clusters. It may also be helpful to be able to fix the
location of selected phenotypes to see how the others move relatively when parameters
are changed. There may also be a more optimal rotation for the dimensional reduction,
in 2 dimensions, or possible 3 dimensions. (2) Additionally, the λ parameter does not
currently have any guidance for optimality. Future work in this area could include a
theoretical investigation to determine optimal λ. (3) Methodologically, GPA analyzes
the intersection of SNPs from the different phenotypes. Future work may include looking
at the non-overlapping SNPs to see if there is a way to use that information. (4)
Lastly, we were concerned that summary statistics that came from GWAS with shared
controls might lead to phenotypes that were artificially close in the ShinyGPA plot,
but we simulated some shared control data and found that this phenomenon did not
significantly affect the visualization.
Overall, we believe that ShinyGPA could be an important tool in the broader
context of drug and therapy development. ShinyGPA provides a clear, easy to read output that helps elucidate the pleiotropy among phenotypes, which will lead to improved
diagnoses and treatment of disease.
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